Article info
PDFReview
p53abn Endometrial Cancer: understanding the most aggressive endometrial cancers in the era of molecular classification
- Correspondence to Dr Jessica N McAlpine, Department of Gynecology and Obstetrics, Division Gynecologic Oncology, University of British Columbia, Vancouver, BC V5Z1M7, Canada; jessica.mcalpine{at}vch.ca
Citation
p53abn Endometrial Cancer: understanding the most aggressive endometrial cancers in the era of molecular classification
Publication history
- Received November 16, 2020
- Revision received January 20, 2021
- Accepted January 28, 2021
- First published February 15, 2021.
Online issue publication
June 07, 2021
Article Versions
- Previous version (15 February 2021).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ.